Advertisement

Supportive Care in Cancer

, Volume 21, Issue 3, pp 697–705 | Cite as

Health-related quality of life and inflammatory markers in malignant pleural mesothelioma

  • Steven C. Kao
  • Janette Vardy
  • Rozelle Harvie
  • Mark Chatfield
  • Nico van Zandwijk
  • Stephen Clarke
  • Nick Pavlakis
Original Article

Abstract

Purpose

Malignant pleural mesothelioma (MPM) is a highly aggressive and symptomatic disease. We examined the relationship between health-related quality of life (HRQoL) and inflammatory markers, and the prognostic role of HRQoL in MPM patients.

Methods

MPM patients from two parallel phase II studies (thalidomide alone or thalidomide with chemotherapy) were included. HRQoL was assessed at baseline using the modified Lung Cancer Symptom Scale (LCSS). Baseline inflammatory markers and cytokines were measured. Spearman correlation was used to examine the relationship between inflammatory markers and HRQoL measures. The prognostic value of the HRQoL domains was examined using Cox proportional hazard model.

Results

Sixty-three patients were included: median age 61 years (range 44–79); 82 % male; 77 % Eastern Cooperative Oncology Group (ECOG) performance status 0–1; 44 % epithelial histology subtype. Baseline systemic symptoms of anorexia and fatigue, the summation symptoms of overall symptomatic distress, interference with normal activity and global QoL and the aggregate score of total LCSS score were all associated with elevated neutrophil-to-lymphocyte ratio, C-reactive protein and vascular endothelial growth factor levels at baseline (rho ≥ 0.25; p < 0.05). Baseline anorexia, fatigue, cough, dyspnoea, pain, overall symptomatic distress, interference with normal activity, global QoL and total LCSS score were all significantly related to survival (p < 0.05) after adjusting for established prognostic factors (age, gender, histological subtype and performance status) and treatment effect.

Conclusions

In conclusion, HRQoL seems to relate to a patient's systemic inflammatory status and is associated with survival in MPM patients.

Keywords

Cancer Health-related quality of life Lung cancer symptom scale Malignant mesothelioma Sickness behaviour Systemic inflammation 

Notes

Acknowledgment

This project was funded by the New South Wales Dust Diseases Compensation Board and the Estate of Mr. Clem Johnson, for financial support and Eli-Lilly for pharmaceutical support (supply of gemcitabine).

SCH Kao is supported by a National Health & Medical Research Council (NHMRC) postgraduate scholarship and a Research Scholar Award from the NSW Cancer Institute.

J Vardy is supported by the NSW Cancer Institute.

Conflict of interest statement

N Pavlakis is on an advisory board with E Lilly and has received a travel grant and speaking honoraria from E Lilly. N. van Zandwijk declares the following: advisory board for E Lilly, Merk Serono and Pfizer; speaker at Lilly Symposia.

References

  1. 1.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644PubMedCrossRefGoogle Scholar
  2. 2.
    Hollen PJ, Gralla RJ, Liepa AM, Symanowski J, Rusthoven J (2006) Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso. Support Care Cancer 14:11–21PubMedCrossRefGoogle Scholar
  3. 3.
    Nowak AK, Stockler MR, Byrne MJ (2004) Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the european organization for research and treatment of cancer core quality of life questionnaire and lung cancer module. J Clin Oncol 22:3172–3180PubMedCrossRefGoogle Scholar
  4. 4.
    Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26:1355–1363PubMedCrossRefGoogle Scholar
  5. 5.
    Quinten C, Coens C, Mauer M, Comte S, Sprangers MAG, Cleeland C, Osoba D, Bjordal K, Bottomley A, Clinical Groups EORTC (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10:865–871PubMedCrossRefGoogle Scholar
  6. 6.
    Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, van Meerbeeck JP, EORTC-NCIC (2007) Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 25:5770–5776PubMedCrossRefGoogle Scholar
  7. 7.
    Kelley K, Bluthe R, Dantzer R, Zhou JH, Shen WH, Johnson RW, Broussard SR (2003) Cytokine-induced sickness behavior. Brain Behav Immun 17:S112–S118PubMedCrossRefGoogle Scholar
  8. 8.
    Dantzer R (2004) Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 500:399–411PubMedCrossRefGoogle Scholar
  9. 9.
    Myers J (2008) Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol Nurs Forum 35:916–920PubMedCrossRefGoogle Scholar
  10. 10.
    Seruga B, Zhang H, Bernstein LJ, Tannock IF (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8:887–899PubMedCrossRefGoogle Scholar
  11. 11.
    Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366:397–408PubMedCrossRefGoogle Scholar
  12. 12.
    Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ (2010) High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16:5805–5813PubMedCrossRefGoogle Scholar
  13. 13.
    Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B (2011) Low calretinin expression and high Neutrophil-to-Lymphocyte Ratio are poor prognostic factors in malignant mesothelioma patients undergoing extrapleural pneumonectomy. J Thorac Oncol 6:1923–1929PubMedCrossRefGoogle Scholar
  14. 14.
    Zahorec R (2001) Ratio of neutrophil to lymphocyte counts—rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 102:5–14PubMedGoogle Scholar
  15. 15.
    Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL (2006) Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardio 97:993–996CrossRefGoogle Scholar
  16. 16.
    Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil–lymphocyte ratio as a prognsotic factor in colorectal cancer. J Surg Oncol 91:181–184PubMedCrossRefGoogle Scholar
  17. 17.
    Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR (2008) Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 97:513–518PubMedCrossRefGoogle Scholar
  18. 18.
    Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E (2009) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 137:425–428PubMedCrossRefGoogle Scholar
  19. 19.
    Chua W, Charles KA, Baracos VE, Clarke SJ (2011) Neutrophil–lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Brit J Cancer 104:1288–1295PubMedCrossRefGoogle Scholar
  20. 20.
    Kao SC, Harvie R, Paturi F, Taylor R, Davey R, Abraham R, Clarke S, Marx G, Cullen M, Kerestes Z, Pavlakis N (2012) The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer 75:248–254PubMedCrossRefGoogle Scholar
  21. 21.
    Hollen P, Gralla R, Kris M (1995) An overview of the Lung Cancer Symptom Scale. In: Gralla R, Moinpour C (eds) Assessing quality of life in patients with lung cancer: a guide for clinicians. NCM Publishers, New York, pp 57–59Google Scholar
  22. 22.
    Schroeder MA (1990) Diagnosing and dealing with multicollinearity. West J Nurs Res 12:175–187PubMedCrossRefGoogle Scholar
  23. 23.
    van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G, European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881–6889PubMedCrossRefGoogle Scholar
  24. 24.
    Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE (2007) The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 21:413–427PubMedCrossRefGoogle Scholar
  25. 25.
    Wang X, Shi Q, Williams L, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z (2010) Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 24:968–974PubMedCrossRefGoogle Scholar
  26. 26.
    Pusztai L, Mendoza T, Reuben J, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25:94–102PubMedCrossRefGoogle Scholar
  27. 27.
    Jones LW, Eves ND, Mackey JR, Peddle CJ, Haykowsky M, Joy AA, Tankel K, Courneya KS, Reiman T (2008) Systemic inflammation, cardiorespiratory fitness, and quality of life in patients with advanced non-small cell lung cancer. J Thorac Oncol 3:194–195PubMedCrossRefGoogle Scholar
  28. 28.
    Brown DJF, McMillan DC, Milroy R (2005) The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer 103:377–382PubMedCrossRefGoogle Scholar
  29. 29.
    Scott HR, McMillan DC, Brown DJF, Forrest LM, McArdle CS, Milroy R (2003) A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in paitnets with inoperable non-small cell lung cancer. Lung Cancer 40:295–299PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Steven C. Kao
    • 1
    • 2
    • 3
  • Janette Vardy
    • 1
    • 3
  • Rozelle Harvie
    • 4
  • Mark Chatfield
    • 5
  • Nico van Zandwijk
    • 2
    • 3
  • Stephen Clarke
    • 3
    • 4
  • Nick Pavlakis
    • 3
    • 4
  1. 1.Department of Medical OncologySydney Cancer CentreSydneyAustralia
  2. 2.Asbestos Diseases Research InstituteSydneyAustralia
  3. 3.Faculty of MedicineUniversity of SydneySydneyAustralia
  4. 4.Department of Medical OncologyRoyal North Shore HospitalSydneyAustralia
  5. 5.NHMRC Clinical Trials CentreSydneyAustralia

Personalised recommendations